Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2008 (2008), Article ID 524671, 15 pages
http://dx.doi.org/10.1155/2008/524671
Review Article

The Role of PPAR Ligands in Controlling Growth-Related Gene Expression and their Interaction with Lipoperoxidation Products

1Dipartimento di Medicina e Oncologia Sperimentale, Sezione di Patologia Generale, Corso Raffaello 30, 10125 Torino, Italy
2Istituto di Ricerche Biomediche “A. Marxer” RBM Merck Serono, Via Ribes 1, 10010 Colleretto Giacosa (Torino), Italy
3Dipartimento di Anatomia, Farmacologia e Medicina Legale, sezione di Farmacologia, Via P. Giuria 13, 10125 Torino, Italy

Received 23 April 2008; Accepted 5 June 2008

Academic Editor: Dipak Panigrahy

Copyright © 2008 Giuseppina Barrera et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. N. A. Palmer, M.-H. Hsu, K. J. Griffin, and E. F. Johnson, “Novel sequence determinants in peroxisome proliferator signaling,” The Journal of Biological Chemistry, vol. 270, no. 27, pp. 16114–16121, 1995. View at Publisher · View at Google Scholar
  2. R. Hess, W. Stäubli, and W. Riess, “Nature of the hepatomegalic effect produced by ethyl-chlorophenoxy-isobutyrate in the rat,” Nature, vol. 208, no. 5013, pp. 856–858, 1965. View at Publisher · View at Google Scholar
  3. T. M. Willson, P. J. Brown, D. D. Sternbach, and B. R. Henke, “The PPARs: from orphan receptors to drug discovery,” Journal of Medicinal Chemistry, vol. 43, no. 4, pp. 527–550, 2000. View at Publisher · View at Google Scholar
  4. I. Issemann and S. Green, “Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators,” Nature, vol. 347, no. 6294, pp. 645–650, 1990. View at Publisher · View at Google Scholar · View at PubMed
  5. R. C. Cattley, J. DeLuca, C. Elcombe et al., “Do peroxisome proliferating compounds pose a hepatocarcinogenic hazard to humans?,” Regulatory Toxicology and Pharmacology, vol. 27, no. 1, pp. 47–60, 1998. View at Publisher · View at Google Scholar · View at PubMed
  6. P. Tontonoz, J. B. Kim, R. A. Graves, and B. M. Spiegelman, “ADD1: a novel helix-loop-helix transcription factor associated with adipocyte determination and differentiation,” Molecular and Cellular Biology, vol. 13, no. 8, pp. 4753–4759, 1993. View at Google Scholar
  7. P. Escher, O. Braissant, S. Basu-Modak, L. Michalik, W. Wahli, and B. Desvergne, “Rat PPARs: quantitative analysis in adult rat tissues and regulation in fasting and refeeding,” Endocrinology, vol. 142, no. 10, pp. 4195–4202, 2001. View at Publisher · View at Google Scholar
  8. G. D. Barish, V. A. Narkar, and R. M. Evans, “PPARδ: a dagger in the heart of the metabolic syndrome,” The Journal of Clinical Investigation, vol. 116, no. 3, pp. 590–597, 2006. View at Publisher · View at Google Scholar · View at PubMed
  9. A. I. Shulman and D. J. Mangelsdorf, “Retinoid X receptor heterodimers in the metabolic syndrome,” The New England Journal of Medicine, vol. 353, no. 6, pp. 604–615, 2005. View at Publisher · View at Google Scholar · View at PubMed
  10. S. A. Kliewer, H. E. Xu, M. H. Lambert, and T. M. Willson, “Peroxisome proliferator-activated receptors: from genes to physiology,” Recent Progress in Hormone Research, vol. 56, pp. 239–265, 2001. View at Publisher · View at Google Scholar
  11. C. K. Glass and S. Ogawa, “Combinatorial roles of nuclear receptors in inflammation and immunity,” Nature Reviews Immunology, vol. 6, no. 1, pp. 44–55, 2006. View at Publisher · View at Google Scholar · View at PubMed
  12. W. Yang, C. Rachez, and L. P. Freedman, “Discrete roles for peroxisome proliferator-activated receptor γ and retinoid X receptor in recruiting nuclear receptor coactivators,” Molecular and Cellular Biology, vol. 20, no. 21, pp. 8008–8017, 2000. View at Publisher · View at Google Scholar
  13. P. Puigserver and B. M. Spiegelman, “Peroxisome proliferator-activated receptor-γ coactivator 1α (PGC-1α): transcriptional coactivator and metabolic regulator,” Endocrine Reviews, vol. 24, no. 1, pp. 78–90, 2003. View at Publisher · View at Google Scholar
  14. S. A. Kliewer, K. Umesono, D. J. Noonan, R. A. Heyman, and R. M. Evans, “Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors,” Nature, vol. 358, no. 6389, pp. 771–774, 1992. View at Publisher · View at Google Scholar · View at PubMed
  15. C. N. A. Palmer, M.-H. Hsu, A. S. Muerhoff, K. J. Griffin, and E. F. Johnson, “Interaction of the peroxisome proliferator-activated receptor α with the retinoid X receptor α unmasks a cryptic peroxisome proliferator response element that overlaps an ARP-1-binding site in the CYP4A6 promoter,” The Journal of Biological Chemistry, vol. 269, no. 27, pp. 18083–18089, 1994. View at Google Scholar
  16. H. Castelein, T. Gulick, P. E. Declercq, G. P. Mannaerts, D. D. Moore, and M. I. Baes, “The peroxisome proliferator activated receptor regulates malic enzyme gene expression,” The Journal of Biological Chemistry, vol. 269, no. 43, pp. 26754–26758, 1994. View at Google Scholar
  17. K. Schoonjans, B. Staels, and J. Auwerx, “Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression,” Journal of Lipid Research, vol. 37, no. 5, pp. 907–925, 1996. View at Google Scholar
  18. K. Schoonjans, J. Peinado-Onsurbe, A.-M. Lefebvre et al., “PPARα and PPARγ activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene,” The EMBO Journal, vol. 15, no. 19, pp. 5336–5348, 1996. View at Google Scholar
  19. A. Acín, M. Rodriguez, H. Rique, E. Canet, J. A. Boutin, and J.-P. Galizzi, “Cloning and characterization of the 5 flanking region of the human uncoupling protein 3 (UCP3) gene,” Biochemical and Biophysical Research Communications, vol. 258, no. 2, pp. 278–283, 1999. View at Publisher · View at Google Scholar
  20. S. Ghosh and R. Natarajan, “Cloning of the human cholesteryl ester hydrolase promoter: identification of functional peroxisomal proliferator-activated receptor responsive elements,” Biochemical and Biophysical Research Communications, vol. 284, no. 4, pp. 1065–1070, 2001. View at Publisher · View at Google Scholar · View at PubMed
  21. A. Kassam, J. P. Capone, and R. A. Rachubinski, “The short heterodimer partner receptor differentially modulates peroxisome proliferator-activated receptor α-mediated transcription from the peroxisome proliferator-response elements of the genes encoding the peroxisomal β-oxidation enzymes acyl-CoA oxidase and hydratase-dehydrogenase,” Molecular and Cellular Endocrinology, vol. 176, no. 1-2, pp. 49–56, 2001. View at Publisher · View at Google Scholar
  22. N. Di-Poï, N. S. Tan, L. Michalik, W. Wahli, and B. Desvergne, “Antiapoptotic role of PPARβ in keratinocytes via transcriptional control of the Akt1 signaling pathway,” Molecular Cell, vol. 10, no. 4, pp. 721–733, 2002. View at Publisher · View at Google Scholar
  23. K. T. Iida, Y. Kawakami, H. Suzuki et al., “PPARγ ligands, troglitazone and pioglitazone, up-regulate expression of HMG-CoA synthase and HMG-CoA reductase gene in THP-1 macrophages,” FEBS Letters, vol. 520, no. 1–3, pp. 177–181, 2002. View at Publisher · View at Google Scholar
  24. A. Gauthier, G. Vassiliou, F. Benoist, and R. McPherson, “Adipocyte low density lipoprotein receptor-related protein gene expression and function is regulated by peroxisome proliferator-activated receptor γ,” The Journal of Biological Chemistry, vol. 278, no. 14, pp. 11945–11953, 2003. View at Publisher · View at Google Scholar · View at PubMed
  25. Á. Baldán, J. Relat, P. F. Marrero, and D. Haro, “Functional interaction between peroxisome proliferator-activated receptors-α and Mef-2C on human carnitine palmitoyltransferase 1β (CPT1β) gene activation,” Nucleic Acids Research, vol. 32, no. 16, pp. 4742–4749, 2004. View at Publisher · View at Google Scholar · View at PubMed
  26. C. Brouillette, Y. Bossé, L. Pérusse, D. Gaudet, and M.-C. Vohl, “Effect of liver fatty acid binding protein (FABP) T94A missense mutation on plasma lipoprotein responsiveness to treatment with fenofibrate,” Journal of Human Genetics, vol. 49, no. 8, pp. 424–432, 2004. View at Publisher · View at Google Scholar · View at PubMed
  27. P. Targett-Adams, M. J. McElwee, E. Ehrenborg, M. C. Gustafsson, C. N. Palmer, and J. McLauchlan, “A PPAR response element regulates transcription of the gene for human adipose differentiation-related protein,” Biochimica et Biophysica Acta, vol. 1728, no. 1-2, pp. 95–104, 2005. View at Publisher · View at Google Scholar · View at PubMed
  28. S. Mandard, F. Zandbergen, N. S. Tan et al., “The direct peroxisome proliferator-activated receptor target fasting-induced adipose factor (FIAF/PGAR/ANGPTL4) is present in blood plasma as a truncated protein that is increased by fenofibrate treatment,” The Journal of Biological Chemistry, vol. 279, no. 33, pp. 34411–34420, 2004. View at Publisher · View at Google Scholar · View at PubMed
  29. H. Kim, J.-Y. Cha, S.-Y. Kim et al., “Peroxisomal proliferator-activated receptor-γ upregulates glucokinase gene expression in β-cells,” Diabetes, vol. 51, no. 3, pp. 676–685, 2002. View at Publisher · View at Google Scholar
  30. D. Patsouris, S. Mandard, P. J. Voshol et al., “PPARα governs glycerol metabolism,” The Journal of Clinical Investigation, vol. 114, no. 1, pp. 94–103, 2004. View at Publisher · View at Google Scholar · View at PubMed
  31. J. Vatsyayan, C.-T. Lin, H.-L. Peng, and H.-Y. Chang, “Identification of a cis-acting element responsible for negative regulation of the human UDP-glucose dehydrogenase gene expression,” Bioscience, Biotechnology and Biochemistry, vol. 70, no. 2, pp. 401–410, 2006. View at Publisher · View at Google Scholar
  32. T. Degenhardt, A. Saramäki, M. Malinen et al., “Three members of the human pyruvate dehydrogenase kinase gene family are direct targets of the peroxisome proliferator-activated receptor β/δ,” Journal of Molecular Biology, vol. 372, no. 2, pp. 341–355, 2007. View at Publisher · View at Google Scholar · View at PubMed
  33. H. Kim, Y.-K. Koh, T.-H. Kim et al., “Transcriptional activation of SHP by PPAR-γ in liver,” Biochemical and Biophysical Research Communications, vol. 360, no. 2, pp. 301–306, 2007. View at Publisher · View at Google Scholar · View at PubMed
  34. A. T. Coyle, M. B. O'Keeffe, and B. T. Kinsella, “15-deoxy Δ12,14-prostaglandin J2 suppresses transcription by promoter 3 of the human thromboxane A2 receptor gene through peroxisome proliferator-activated receptor γ in human erythroleukemia cells,” FEBS Journal, vol. 272, no. 18, pp. 4754–4773, 2005. View at Publisher · View at Google Scholar · View at PubMed
  35. R. Stienstra, S. Mandard, N. S. Tan et al., “The Interleukin-1 receptor antagonist is a direct target gene of PPARα in liver,” Journal of Hepatology, vol. 46, no. 5, pp. 869–877, 2007. View at Publisher · View at Google Scholar · View at PubMed
  36. I. Jedidi, M. Couturier, P. Thérond et al., “Cholesteryl ester hydroperoxides increase macrophage CD36 gene expression via PPARα,” Biochemical and Biophysical Research Communications, vol. 351, no. 3, pp. 733–738, 2006. View at Publisher · View at Google Scholar · View at PubMed
  37. L. Ravaux, C. Denoyelle, C. Monne, I. Limon, M. Raymondjean, and K. El Hadri, “Inhibition of interleukin-1β-induced group IIA secretory phospholipase A2 expression by peroxisome proliferator-activated receptors (PPARs) in rat vascular smooth muscle cells: cooperation between PPARβ and the proto-oncogene BCL-6,” Molecular and Cellular Biology, vol. 27, no. 23, pp. 8374–8387, 2007. View at Publisher · View at Google Scholar · View at PubMed
  38. P. H. Villard, S. Caverni, A. Baanannou et al., “PPARα transcriptionally induces AhR expression in Caco-2, but represses AhR pro-inflammatory effects,” Biochemical and Biophysical Research Communications, vol. 364, no. 4, pp. 896–901, 2007. View at Publisher · View at Google Scholar · View at PubMed
  39. N. A. Ignatenko, N. Babbar, D. Mehta, R. A. Casero, Jr., and E. W. Gerner, “Suppression of polyamine catabolism by activated Ki-ras in human colon cancer cells,” Molecular Carcinogenesis, vol. 39, no. 2, pp. 91–102, 2004. View at Publisher · View at Google Scholar · View at PubMed
  40. F. Zandbergen, S. Mandard, P. Escher et al., “The G0/G1 switch gene 2 is a novel PPAR target gene,” Biochemical Journal, vol. 392, no. 2, pp. 313–324, 2005. View at Publisher · View at Google Scholar · View at PubMed
  41. L. L. H. Peeters, J.-L. Vigne, M. K. Tee, D. Zhao, L. L. Waite, and R. N. Taylor, “PPARγ represses VEGF expression in human endometrial cells: implications for uterine angiogenesis,” Angiogenesis, vol. 8, no. 4, pp. 373–379, 2006. View at Publisher · View at Google Scholar · View at PubMed
  42. T. Degenhardt, M. Matilainen, K.-H. Herzig, T. W. Dunlop, and C. Carlberg, “The insulin-like growth factor-binding protein 1 gene is a primary target of peroxisome proliferator-activated receptors,” The Journal of Biological Chemistry, vol. 281, no. 51, pp. 39607–39619, 2006. View at Publisher · View at Google Scholar · View at PubMed
  43. E. Sérée, P.-H. Villard, J.-M. Pascussi et al., “Evidence for a new human CYP1A1 regulation pathway involving PPAR-α and 2 PPRE sites,” Gastroenterology, vol. 127, no. 5, pp. 1436–1445, 2004. View at Publisher · View at Google Scholar
  44. E. Y. Park, I. J. Cho, and S. G. Kim, “Transactivation of the PPAR-responsive enhancer module in chemopreventive glutathione S-transferase gene by the peroxisome proliferator-activated receptor-γ and retinoid X receptor heterodimer,” Cancer Research, vol. 64, no. 10, pp. 3701–3713, 2004. View at Publisher · View at Google Scholar · View at PubMed
  45. J. Pandhare, S. K. Cooper, and J. M. Phang, “Proline oxidase, a proapoptotic gene, is induced by troglitazone: evidence for both peroxisome proliferator-activated receptor γ-dependent and -independent mechanisms,” The Journal of Biological Chemistry, vol. 281, no. 4, pp. 2044–2052, 2006. View at Publisher · View at Google Scholar · View at PubMed
  46. L. Billiet, C. Furman, G. Larigauderie et al., “Enhanced VDUP-1 gene expression by PPARγ agonist induces apoptosis in human macrophage,” Journal of Cellular Physiology, vol. 214, no. 1, pp. 183–191, 2008. View at Publisher · View at Google Scholar · View at PubMed
  47. A. Boulanger, P. McLemore, N. G. Copeland et al., “Identification of beta-carotene 15,15-monooxygenase as a peroxisome proliferator-activated receptor target gene,” The FASEB Journal, vol. 17, no. 10, pp. 1304–1306, 2003. View at Publisher · View at Google Scholar · View at PubMed
  48. J. F. Landrier, C. Thomas, J. Grober et al., “The gene encoding the human ileal bile acid-binding protein (I-BABP) is regulated by peroxisome proliferator-activated receptors,” Biochimica et Biophysica Acta, vol. 1735, no. 1, pp. 41–49, 2005. View at Publisher · View at Google Scholar · View at PubMed
  49. E. Efrati, J. Arsentiev-Rozenfeld, and I. Zelikovic, “The human paracellin-1 gene (hPCLN-1): renal epithelial cell-specific expression and regulation,” American Journal of Physiology, vol. 288, no. 2, pp. F272–F283, 2005. View at Publisher · View at Google Scholar · View at PubMed
  50. M. Sastre, I. Dewachter, S. Rossner et al., “Nonsteroidal anti-inflammatory drugs repress β-secretase gene promoter activity by the activation of PPARγ,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 2, pp. 443–448, 2006. View at Publisher · View at Google Scholar · View at PubMed
  51. A. Benigni, C. Zoja, S. Tomasoni et al., “Transcriptional regulation of nephrin gene by peroxisome proliferator-activated receptor-γ agonist: molecular mechanism of the antiproteinuric effect of pioglitazone,” Journal of the American Society of Nephrology, vol. 17, no. 6, pp. 1624–1632, 2006. View at Publisher · View at Google Scholar · View at PubMed
  52. N. Viswakarma, S. Yu, S. Naik et al., “Transcriptional regulation of Cidea, mitochondrial cell death-inducing DNA fragmentation factor α-like effector A, in mouse liver by peroxisome proliferator-activated receptor α and γ,” The Journal of Biological Chemistry, vol. 282, no. 25, pp. 18613–18624, 2007. View at Publisher · View at Google Scholar · View at PubMed
  53. T. Shimada, Y. Fujii, T. Koike et al., “Peroxisome proliferator-activated receptor γ (PPARγ) regulates trefoil factor family 2 (TFF2) expression in gastric epithelial cells,” The International Journal of Biochemistry & Cell Biology, vol. 39, no. 3, pp. 626–637, 2007. View at Publisher · View at Google Scholar · View at PubMed
  54. A.-M. Krogsdam, C. A. F. Nielsen, S. Neve et al., “Nuclear receptor corepressor-dependent repression of peroxisome-proliferator-activated receptor δ-mediated transactivation,” Biochemical Journal, vol. 363, no. 1, pp. 157–165, 2002. View at Publisher · View at Google Scholar
  55. Y. Shi, M. Hon, and R. M. Evans, “The peroxisome proliferator-activated receptor δ, an integrator of transcriptional repression and nuclear receptor signaling,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 5, pp. 2613–2618, 2002. View at Publisher · View at Google Scholar · View at PubMed
  56. L. H. Wang, X. Y. Yang, X. Zhang et al., “Transcriptional inactivation of STAT3 by PPARγ suppresses IL-6-responsive multiple myeloma cells,” Immunity, vol. 20, no. 2, pp. 205–218, 2004. View at Publisher · View at Google Scholar
  57. S. Ghisletti, W. Huang, S. Ogawa et al., “Parallel SUMOylation-dependent pathways mediate gene- and signal-specific transrepression by LXRs and PPARγ,” Molecular Cell, vol. 25, no. 1, pp. 57–70, 2007. View at Publisher · View at Google Scholar · View at PubMed
  58. C.-H. Lee, A. Chawla, N. Urbiztondo, D. Liao, W. A. Boisvert, and R. M. Evans, “Transcriptional repression of atherogenic inflammation: modulation by PPARδ,” Science, vol. 302, no. 5644, pp. 453–457, 2003. View at Publisher · View at Google Scholar · View at PubMed
  59. P. Delerive, J.-C. Fruchart, and B. Staels, “Peroxisome proliferator-activated receptors in inflammation control,” Journal of Endocrinology, vol. 169, no. 3, pp. 453–459, 2001. View at Publisher · View at Google Scholar
  60. T. M. Willson and W. Wahli, “Peroxisome proliferator-activated receptor agonists,” Current Opinion in Chemical Biology, vol. 1, no. 2, pp. 235–241, 1997. View at Publisher · View at Google Scholar
  61. W. Ahmed, O. Ziouzenkova, J. Brown et al., “PPARs and their metabolic modulation: new mechanisms for transcriptional regulation?,” Journal of Internal Medicine, vol. 262, no. 2, pp. 184–198, 2007. View at Publisher · View at Google Scholar · View at PubMed
  62. G. Krey, O. Braissant, F. L'Horset et al., “Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay,” Molecular Endocrinology, vol. 11, no. 6, pp. 779–791, 1997. View at Publisher · View at Google Scholar
  63. S. A. Kliewer, S. S. Sundseth, S. A. Jones et al., “Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 9, pp. 4318–4323, 1997. View at Publisher · View at Google Scholar
  64. B. M. Forman, J. Chen, and R. M. Evans, “Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 9, pp. 4312–4317, 1997. View at Publisher · View at Google Scholar
  65. P. R. Devchand, H. Keller, J. M. Peters, M. Vazquez, F. J. Gonzalez, and W. Wahli, “The PPARα-leukotriene B4 pathway to inflammation control,” Nature, vol. 384, no. 6604, pp. 39–43, 1996. View at Publisher · View at Google Scholar · View at PubMed
  66. S. Sethi, O. Ziouzenkova, H. Ni, D. D. Wagner, J. Plutzky, and T. N. Mayadas, “Oxidized omega-3 fatty acids in fish oil inhibit leukocyte-endothelial interactions through activation of PPARα,” Blood, vol. 100, no. 4, pp. 1340–1346, 2002. View at Publisher · View at Google Scholar · View at PubMed
  67. S. Theocharis, A. Margeli, P. Vielh, and G. Kouraklis, “Peroxisome proliferator-activated receptor-γ ligands as cell-cycle modulators,” Cancer Treatment Reviews, vol. 30, no. 6, pp. 545–554, 2004. View at Publisher · View at Google Scholar · View at PubMed
  68. S. A. Kliewer, J. M. Lenhard, T. M. Willson, I. Patel, D. C. Morris, and J. M. Lehmann, “A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation,” Cell, vol. 83, no. 5, pp. 813–819, 1995. View at Publisher · View at Google Scholar
  69. C. M. Komar, “Peroxisome proliferator-activated receptors (PPARs) and ovarian function—implications for regulating steroidogenesis, differentiation, and tissue remodeling,” Reproductive Biology and Endocrinology, vol. 3, article 41, 2005. View at Publisher · View at Google Scholar · View at PubMed
  70. J. D. Brown and J. Plutzky, “Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets,” Circulation, vol. 115, no. 4, pp. 518–533, 2007. View at Publisher · View at Google Scholar · View at PubMed
  71. B. M. Forman, J. Chen, and R. M. Evans, “The peroxisome proliferator-activated receptors: ligands and activators,” Annals of the New York Academy of Sciences, vol. 804, pp. 266–275, 1996. View at Publisher · View at Google Scholar
  72. B. Staels and J.-C. Fruchart, “Therapeutic roles of peroxisome proliferator-activated receptor agonists,” Diabetes, vol. 54, no. 8, pp. 2460–2470, 2005. View at Publisher · View at Google Scholar
  73. J. M. Lehmann, L. B. Moore, T. A. Smith-Oliver, W. O. Wilkison, T. M. Willson, and S. A. Kliewer, “An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ),” The Journal of Biological Chemistry, vol. 270, no. 22, pp. 12953–12956, 1995. View at Publisher · View at Google Scholar
  74. M. Lehrke and M. A. Lazar, “The many faces of PPARγ,” Cell, vol. 123, no. 6, pp. 993–999, 2005. View at Publisher · View at Google Scholar · View at PubMed
  75. J. M. Lehmann, J. M. Lenhard, B. B. Oliver, G. M. Ringold, and S. A. Kliewer, “Peroxisome proliferator-activated receptors α and γ are activated by indomethacin and other non-steroidal anti-inflammatory drugs,” The Journal of Biological Chemistry, vol. 272, no. 6, pp. 3406–3410, 1997. View at Publisher · View at Google Scholar
  76. D. J. A. Adamson, D. Frew, R. Tatoud, C. R. Wolf, and C. N. A. Palmer, “Diclofenac antagonizes peroxisome proliferator-activated receptor-γ signaling,” Molecular Pharmacology, vol. 61, no. 1, pp. 7–12, 2002. View at Publisher · View at Google Scholar
  77. M. D. Leibowitz, C. Fiévet, N. Hennuyer et al., “Activation of PPARδ alters lipid metabolism in db/db mice,” FEBS Letters, vol. 473, no. 3, pp. 333–336, 2000. View at Publisher · View at Google Scholar
  78. W. R. Oliver, Jr., J. L. Shenk, M. R. Snaith et al., “A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 9, pp. 5306–5311, 2001. View at Publisher · View at Google Scholar · View at PubMed
  79. T.-C. He, T. A. Chan, B. Vogelstein, and K. W. Kinzler, “PPARδ is an APC-regulated target of nonsteroidal anti-inflammatory drugs,” Cell, vol. 99, no. 3, pp. 335–345, 1999. View at Publisher · View at Google Scholar
  80. L. Xu, C. Han, and T. Wu, “A novel positive feedback loop between peroxisome proliferator-activated receptor-δ and prostaglandin E2 signaling pathways for human cholangiocarcinoma cell growth,” The Journal of Biological Chemistry, vol. 281, no. 45, pp. 33982–33996, 2006. View at Publisher · View at Google Scholar · View at PubMed
  81. M. W. Matthiessen, G. Pedersen, T. Albrektsen, S. Adamsen, J. Fleckner, and J. Brynskov, “Peroxisome proliferator-activated receptor expression and activation in normal human colonic epithelial cells and tubular adenomas,” Scandinavian Journal of Gastroenterology, vol. 40, no. 2, pp. 198–205, 2005. View at Publisher · View at Google Scholar · View at PubMed
  82. K. Fukumoto, Y. Yano, N. Virgona et al., “Peroxisome proliferator-activated receptor δ as a molecular target to regulate lung cancer cell growth,” FEBS Letters, vol. 579, no. 17, pp. 3829–3836, 2005. View at Publisher · View at Google Scholar · View at PubMed
  83. F. Y. Ali, K. Egan, G. A. FitzGerald et al., “Role of prostacyclin versus peroxisome proliferator-activated receptor β receptors in prostacyclin sensing by lung fibroblasts,” American Journal of Respiratory Cell and Molecular Biology, vol. 34, no. 2, pp. 242–246, 2006. View at Publisher · View at Google Scholar · View at PubMed
  84. A. Planavila, R. Rodríguez-Calvo, M. Jové et al., “Peroxisome proliferator-activated receptor β/δ activation inhibits hypertrophy in neonatal rat cardiomyocytes,” Cardiovascular Research, vol. 65, no. 4, pp. 832–841, 2005. View at Publisher · View at Google Scholar · View at PubMed
  85. G. Martinasso, M. Maggiora, A. Trombetta, R. A. Canuto, and G. Muzio, “Effects of di(2-ethylhexyl) phthalate, a widely used peroxisome proliferator and plasticizer, on cell growth in the human keratino cyte cell line NCTC 2544,” Journal of Toxicology and Environmental Health, Part A, vol. 69, no. 5, pp. 353–365, 2006. View at Publisher · View at Google Scholar · View at PubMed
  86. M. Westergaard, J. Henningsen, M. L. Svendsen et al., “Modulation of keratinocyte gene expression and differentiation by PPAR-selective ligands and tetradecylthioacetic acid,” Journal of Investigative Dermatology, vol. 116, no. 5, pp. 702–712, 2001. View at Google Scholar
  87. D. J. Kim, M. T. Bility, A. N. Billin, T. M. Willson, F. J. Gonzalez, and J. M. Peters, “PPARβ/δ selectively induces differentiation and inhibits cell proliferation,” Cell Death & Differentiation, vol. 13, no. 1, pp. 53–60, 2006. View at Publisher · View at Google Scholar · View at PubMed
  88. A. Nilsson, A. K. Ostlund Farrants, J. M. Nesland, H. S. Finstad, and J. I. Pedersen, “Potentiating effects of clofibric acid on the differentiation of HL-60 human promyelocytic leukemia cells induced by retinoids,” European Journal of Cell Biology, vol. 67, no. 4, pp. 379–385, 1995. View at Google Scholar
  89. K. Hanley, Y. Jiang, S. S. He et al., “Keratinocyte differentiation is stimulated by activators of the nuclear hormone receptor PPARα,” Journal of Investigative Dermatology, vol. 110, no. 4, pp. 368–375, 1998. View at Publisher · View at Google Scholar · View at PubMed
  90. M. Bronfman, C. Ponce, S. Rojas et al., “Enhanced differentiation of HL-60 leukemia cells to macrophages induced by ciprofibrate,” European Journal of Cell Biology, vol. 77, no. 3, pp. 214–219, 1998. View at Google Scholar
  91. R. Scatena, G. Nocca, P. D. Sole et al., “Bezafibrate as differentiating factor of human myeloid leukemia cells,” Cell Death & Differentiation, vol. 6, no. 8, pp. 781–787, 1999. View at Google Scholar
  92. G. D. Demetri, C. D. M. Fletcher, E. Mueller et al., “Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-γ ligand troglitazone in patients with liposarcoma,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 7, pp. 3951–3956, 1999. View at Google Scholar
  93. E. Mueller, P. Sarraf, P. Tontonoz et al., “Terminal differentiation of human breast cancer through PPARγ,” Molecular Cell, vol. 1, no. 3, pp. 465–470, 1998. View at Publisher · View at Google Scholar
  94. S. Pizzimenti, S. Laurora, F. Briatore, C. Ferretti, M. U. Dianzani, and G. Barrera, “Synergistic effect of 4-hydroxynonenal and PPAR ligands in controlling human leukemic cell growth and differentiation,” Free Radical Biology and Medicine, vol. 32, no. 3, pp. 233–245, 2002. View at Publisher · View at Google Scholar
  95. M. Schmuth, C. M. Haqq, W. J. Cairns et al., “Peroxisome proliferator-activated receptor (PPAR)-β/δ stimulates differentiation and lipid accumulation in keratinocytes,” Journal of Investigative Dermatology, vol. 122, no. 4, pp. 971–983, 2004. View at Publisher · View at Google Scholar · View at PubMed
  96. N. S. Tan, L. Michalik, N. Noy et al., “Critical roles of PPARβ/δ in keratinocyte response to inflammation,” Genes & Development, vol. 15, no. 24, pp. 3263–3277, 2001. View at Publisher · View at Google Scholar · View at PubMed
  97. C. S. Aung, H. M. Faddy, E. J. Lister, G. R. Monteith, and S. J. Roberts-Thomson, “Isoform specific changes in PPARα and β in colon and breast cancer with differentiation,” Biochemical and Biophysical Research Communications, vol. 340, no. 2, pp. 656–660, 2006. View at Publisher · View at Google Scholar · View at PubMed
  98. H. Vosper, L. Patel, T. L. Graham et al., “The peroxisome proliferator-activated receptor δ promotes lipid accumulation in human macrophages,” The Journal of Biological Chemistry, vol. 276, no. 47, pp. 44258–44265, 2001. View at Publisher · View at Google Scholar · View at PubMed
  99. I. Saluja, J. G. Granneman, and R. P. Skoff, “PPAR δ agonists stimulate oligodendrocyte differentiation in tissue culture,” Glia, vol. 33, no. 3, pp. 191–204, 2001. View at Publisher · View at Google Scholar
  100. S. Laurora, S. Pizzimenti, F. Briatore et al., “Peroxisome proliferator-activated receptor ligands affect growth-related gene expression in human leukemic cells,” Journal of Pharmacology and Experimental Therapeutics, vol. 305, no. 3, pp. 932–942, 2003. View at Publisher · View at Google Scholar · View at PubMed
  101. L. Fajas, M.-B. Debril, and J. Auwerx, “Peroxisome proliferator-activated receptor-γ: from adipogenesis to carcinogenesis,” Journal of Molecular Endocrinology, vol. 27, no. 1, pp. 1–9, 2001. View at Publisher · View at Google Scholar
  102. H. Asou, W. Verbeek, E. Williamson et al., “Growth inhibition of myeloid leukaemia cells by troglitazone, a ligand for peroxisome proliferator activated receptor gamma, and retinoids,” International Journal of Oncology, vol. 15, no. 5, pp. 1027–1031, 1999. View at Google Scholar
  103. F. Yin, S. Wakino, Z. Liu et al., “Troglitazone inhibits growth of MCF-7 breast carcinoma cells by targeting G1 cell cycle regulators,” Biochemical and Biophysical Research Communications, vol. 286, no. 5, pp. 916–922, 2001. View at Publisher · View at Google Scholar · View at PubMed
  104. R. F. Morrison and S. R. Farmer, “Role of PPARγ in regulating a cascade expression of cyclin-dependent kinase inhibitors, p18(INK4c) and p21(Waf1/Cip1), during adipogenesis,” The Journal of Biological Chemistry, vol. 274, no. 24, pp. 17088–17097, 1999. View at Publisher · View at Google Scholar
  105. C. Giacinti and A. Giordano, “RB and cell cycle progression,” Oncogene, vol. 25, no. 38, pp. 5220–5227, 2006. View at Publisher · View at Google Scholar · View at PubMed
  106. S. Wakino, U. Kintscher, S. Kim, F. Yin, W. A. Hsueh, and R. E. Law, “Peroxisome proliferator-activated receptor γ ligands inhibit retinoblastoma phosphorylation and G1S transition in vascular smooth muscle cells,” The Journal of Biological Chemistry, vol. 275, no. 29, pp. 22435–22441, 2000. View at Publisher · View at Google Scholar · View at PubMed
  107. S. T. de Dios, D. Bruemmer, R. J. Dilley et al., “Inhibitory activity of clinical thiazolidinedione peroxisome proliferator activating receptor-γ ligands toward internal mammary artery, radial artery, and saphenous vein smooth muscle cell proliferation,” Circulation, vol. 107, no. 20, pp. 2548–2550, 2003. View at Publisher · View at Google Scholar · View at PubMed
  108. D. Bruemmer, J. P. Berger, J. Liu et al., “A non-thiazolidinedione partial peroxisome proliferator-activated receptor γ ligand inhibits vascular smooth muscle cell growth,” European Journal of Pharmacology, vol. 466, no. 3, pp. 225–234, 2003. View at Publisher · View at Google Scholar
  109. S. Kawa, T. Nikaido, H. Unno, N. Usuda, K. Nakayama, and K. Kiyosawa, “Growth inhibition and differentiation of pancreatic cancer cell lines by PPARγ ligand troglitazone,” Pancreas, vol. 24, no. 1, pp. 1–7, 2002. View at Publisher · View at Google Scholar
  110. A. D. Burdick, M. T. Bility, E. E. Girroir et al., “Ligand activation of peroxisome proliferator-activated receptor-β/δ(PPARβ/δ) inhibits cell growth of human N/TERT-1 keratinocytes,” Cellular Signalling, vol. 19, no. 6, pp. 1163–1171, 2007. View at Publisher · View at Google Scholar · View at PubMed
  111. F.-S. Chou, P.-S. Wang, S. Kulp, and J. J. Pinzone, “Effects of thiazolidinediones on differentiation, proliferation, and apoptosis,” Molecular Cancer Research, vol. 5, no. 6, pp. 523–530, 2007. View at Publisher · View at Google Scholar · View at PubMed
  112. Y. Kim, N. Suh, M. Sporn, and J. C. Reed, “An inducible pathway for degradation of FLIP protein sensitizes tumor cells to TRAIL-induced apoptosis,” The Journal of Biological Chemistry, vol. 277, no. 25, pp. 22320–22329, 2002. View at Publisher · View at Google Scholar · View at PubMed
  113. T. Shimada, K. Kojima, K. Yoshiura, H. Hiraishi, and A. Terano, “Characteristics of the peroxisome proliferator activated receptor γ (PPARγ) ligand induced apoptosis in colon cancer cells,” Gut, vol. 50, no. 5, pp. 658–664, 2002. View at Publisher · View at Google Scholar
  114. M. Toyoda, H. Takagi, N. Horiguchi et al., “A ligand for peroxisome proliferator activated receptor γ inhibits cell growth and induces apoptosis in human liver cancer cells,” Gut, vol. 50, no. 4, pp. 563–567, 2002. View at Publisher · View at Google Scholar
  115. E. Elstner, C. Müller, K. Koshizuka et al., “Ligands for peroxisome proliferator-activated receptorγ and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 15, pp. 8806–8811, 1998. View at Google Scholar
  116. C. E. Clay, G. Atsumi, K. P. High, and F. H. Chilton, “Early de novo gene expression is required for 15-deoxy-Δ12,14-prostaglandin J2-induced apoptosis in breast cancer cells,” The Journal of Biological Chemistry, vol. 276, no. 50, pp. 47131–47135, 2001. View at Publisher · View at Google Scholar · View at PubMed
  117. M. Kondo, T. Shibata, T. Kumagai et al., “15-deoxy-Δ12,14-prostaglandin J2: the endogenous electrophile that induces neuronal apoptosis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 11, pp. 7367–7372, 2002. View at Publisher · View at Google Scholar · View at PubMed
  118. M. S. Lin, W. C. Chen, X. Bai, and Y. D. Wang, “Activation of peroxisome proliferator-activated receptor γ inhibits cell growth via apoptosis and arrest of the cell cycle in human colorectal cancer,” Journal of Digestive Diseases, vol. 8, no. 2, pp. 82–88, 2007. View at Publisher · View at Google Scholar · View at PubMed
  119. H. Liu, C. Zang, M. H. Fenner et al., “Growth inhibition and apoptosis in human Philadelphia chromosome-positive lymphoblastic leukemia cell lines by treatment with the dual PPARα/γ ligand TZD18,” Blood, vol. 107, no. 9, pp. 3683–3692, 2006. View at Publisher · View at Google Scholar · View at PubMed
  120. G. Muzio, G. Martinasso, A. Trombetta, D. Di Simone, R. A. Canuto, and M. Maggiora, “HMG-CoA reductase and PPARα are involved in clofibrate-induced apoptosis in human keratinocytes,” Apoptosis, vol. 11, no. 2, pp. 265–275, 2006. View at Publisher · View at Google Scholar · View at PubMed
  121. T. Shigeto, Y. Yokoyama, B. Xin, and H. Mizunuma, “Peroxisome proliferator-activated receptor α and γ ligands inhibit the growth of human ovarian cancer,” Oncology Reports, vol. 18, no. 4, pp. 833–840, 2007. View at Google Scholar
  122. G. Muzio, M. Maggiora, M. Oraldi, A. Trombetta, and R. A. Canuto, “PPARα and PP2A are involved in the proapoptotic effect of conjugated linoleic acid on human hepatoma cell line SK-HEP-1,” International Journal of Cancer, vol. 121, no. 11, pp. 2395–2401, 2007. View at Publisher · View at Google Scholar · View at PubMed
  123. R. A. Gupta, D. Wang, S. Katkuri, H. Wang, S. K. Dey, and R. N. DuBois, “Activation of nuclear hormone receptor peroxisome proliferator-activated receptor-δ accelerates intestinal adenoma growth,” Nature Medicine, vol. 10, no. 3, pp. 245–247, 2004. View at Publisher · View at Google Scholar · View at PubMed
  124. D. Wang, H. Wang, Q. Shi et al., “Prostaglandin E2 promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor δ,” Cancer Cell, vol. 6, no. 3, pp. 285–295, 2004. View at Publisher · View at Google Scholar · View at PubMed
  125. L. Michalik, B. Desvergne, N. S. Tan et al., “Impaired skin wound healing in peroxisome proliferator-activated receptor (PPAR)α and PPARβ mutant mice,” The Journal of Cell Biology, vol. 154, no. 4, pp. 799–814, 2001. View at Publisher · View at Google Scholar · View at PubMed
  126. J. M. Peters, S. S. T. Lee, W. Li et al., “Growths, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor β(δ),” Molecular and Cellular Biology, vol. 20, no. 14, pp. 5119–5128, 2000. View at Publisher · View at Google Scholar
  127. T. Hatae, M. Wada, C. Yokoyama, M. Shimonishi, and T. Tanabe, “Prostacyclin-dependent apoptosis mediated by PPARδ,” The Journal of Biological Chemistry, vol. 276, no. 49, pp. 46260–46267, 2001. View at Publisher · View at Google Scholar · View at PubMed
  128. R. A. Gupta, J. A. Brockman, P. Sarraf, T. M. Willson, and R. N. DuBois, “Target genes of peroxisome proliferator-activated receptor γ in colorectal cancer cells,” The Journal of Biological Chemistry, vol. 276, no. 32, pp. 29681–29687, 2001. View at Publisher · View at Google Scholar · View at PubMed
  129. S. Altiok, M. Xu, and B. M. Spiegelman, “PPARγ induces cell cycle withdrawal: inhibition of E2f/DP DNA-binding activity via down-regulation of PP2A,” Genes & Development, vol. 11, no. 15, pp. 1987–1998, 1997. View at Google Scholar
  130. H. P. Koeffler, “Peroxisome proliferator-activated receptor γ and cancers,” Clinical Cancer Research, vol. 9, no. 1, pp. 1–9, 2003. View at Google Scholar
  131. N. Yamakawa-Karakida, K. Sugita, T. Inukai et al., “Ligand activation of peroxisome proliferator-activated receptor γ induces apoptosis of leukemia cells by down-regulating the c-myc gene expression via blockade of the Tcf-4 activity,” Cell Death & Differentiation, vol. 9, no. 5, pp. 513–526, 2002. View at Publisher · View at Google Scholar · View at PubMed
  132. A. Cerbone, C. Toaldo, S. Laurora et al., “4-hydroxynonenal and PPARγ ligands affect proliferation, differentiation, and apoptosis in colon cancer cells,” Free Radical Biology and Medicine, vol. 42, no. 11, pp. 1661–1670, 2007. View at Publisher · View at Google Scholar · View at PubMed
  133. F. Bozzo, C. Bocca, S. Colombatto, and A. Miglietta, “Antiproliferative effect of conjugated linoleic acid in caco-2 cells: involvement of PPARγ and APC/β-catenin pathways,” Chemico-Biological Interactions, vol. 169, no. 2, pp. 110–121, 2007. View at Publisher · View at Google Scholar · View at PubMed
  134. N. Marui, T. Sakai, N. Hosokawa et al., “N-myc suppression and cell cycle arrest at G1 phase by prostaglandins,” FEBS Letters, vol. 270, no. 1-2, pp. 15–18, 1990. View at Publisher · View at Google Scholar
  135. T. Okura, M. Nakamura, Y. Takata, S. Watanabe, Y. Kitami, and K. Hiwada, “Troglitazone induces apoptosis via the p53 and Gadd45 pathway in vascular smooth muscle cells,” European Journal of Pharmacology, vol. 407, no. 3, pp. 227–235, 2000. View at Publisher · View at Google Scholar
  136. S. S. Palakurthi, H. Aktas, L. M. Grubissich, R. M. Mortensen, and J. A. Halperin, “Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor γ and mediated by inhibition of translation initiation,” Cancer Research, vol. 61, no. 16, pp. 6213–6218, 2001. View at Google Scholar
  137. I. Gouni-Berthold, H. K. Berthold, A.-A. Weber et al., “Troglitazone and rosiglitazone induce apoptosis of vascular smooth muscle cells through an extracellular signal-regulated kinase-independent pathway,” Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 363, no. 2, pp. 215–221, 2001. View at Publisher · View at Google Scholar
  138. K. Takeda, T. Ichiki, T. Tokunou, N. Iino, and A. Takeshita, “15-deoxy-Δ12,14-prostaglandin J2 and thiazolidinediones activate the MEK/ERK pathway through phosphatidylinositol 3-kinase in vascular smooth muscle cells,” The Journal of Biological Chemistry, vol. 276, no. 52, pp. 48950–48955, 2001. View at Publisher · View at Google Scholar · View at PubMed
  139. M.-A. Bae and B. J. Song, “Critical role of c-Jun N-terminal protein kinase activation in troglitazone-induced apoptosis of human HepG2 hepatoma cells,” Molecular Pharmacology, vol. 63, no. 2, pp. 401–408, 2003. View at Publisher · View at Google Scholar
  140. S. J. Baek, L. C. Wilson, L. C. Hsi, and T. E. Eling, “Troglitazone, a peroxisome proliferator-activated receptor γ (PPARγ) ligand, selectively induces the early growth response-1 gene independently of PPARγ. A novel mechanism for its anti-tumorigenic activity,” The Journal of Biological Chemistry, vol. 278, no. 8, pp. 5845–5853, 2003. View at Publisher · View at Google Scholar · View at PubMed
  141. W. Motomura, T. Okumura, N. Takahashi, T. Obara, and Y. Kohgo, “Activation of peroxisome proliferator-activated receptor γ by troglitazone inhibits cell growth through the increase of p27Kip1 in human pancreatic carcinoma cells,” Cancer Research, vol. 60, no. 19, pp. 5558–5564, 2000. View at Google Scholar
  142. A. Sugimura, Y. Kiriyama, H. Nochi et al., “Troglitazone suppresses cell growth of myeloid leukemia cell lines by induction of p21WAF1/CIP1 cyclin-dependent kinase inhibitor,” Biochemical and Biophysical Research Communications, vol. 261, no. 3, pp. 833–837, 1999. View at Publisher · View at Google Scholar · View at PubMed
  143. C.-C. Yang, Y.-C. Wang, S. Wei et al., “Peroxisome proliferator-activated receptor γ-independent suppression of androgen receptor expression by troglitazone mechanism and pharmacologic exploitation,” Cancer Research, vol. 67, no. 7, pp. 3229–3238, 2007. View at Publisher · View at Google Scholar · View at PubMed
  144. G. He, Y. M. Sung, J. DiGiovanni, and S. M. Fischer, “Thiazolidinediones inhibit insulin-like growth factor-I-induced activation of p70S6 kinase and suppress insulin-like growth factor-I tumor-promoting activity,” Cancer Research, vol. 66, no. 3, pp. 1873–1878, 2006. View at Publisher · View at Google Scholar · View at PubMed
  145. J.-W. Huang, C.-W. Shiau, Y.-T. Yang et al., “Peroxisome proliferator-activated receptor γ-independent ablation of cyclin D1 by thiazolidinediones and their derivatives in breast cancer cells,” Molecular Pharmacology, vol. 67, no. 4, pp. 1342–1348, 2005. View at Publisher · View at Google Scholar · View at PubMed
  146. K.-H. Kim, Y. S. Cho, J.-M. Park, S.-O. Yoon, K.-W. Kim, and A.-S. Chung, “Pro-MMP-2 activation by the PPARγ agonist, ciglitazone, induces cell invasion through the generation of ROS and the activation of ERK,” FEBS Letters, vol. 581, no. 17, pp. 3303–3310, 2007. View at Publisher · View at Google Scholar · View at PubMed
  147. C. L. Chaffer, D. M. Thomas, E. W. Thompson, and E. D. Williams, “PPARγ-independent induction of growth arrest and apoptosis in prostate and bladder carcinoma,” BMC Cancer, vol. 6, article 53, pp. 1–13, 2006. View at Publisher · View at Google Scholar · View at PubMed
  148. M. Takenokuchi, K. Saigo, Y. Nakamachi et al., “Troglitazone inhibits cell growth and induces apoptosis of B-cell acute lymphoblastic leukemia cells with t(14;18),” Acta Haematologica, vol. 116, no. 1, pp. 30–40, 2006. View at Publisher · View at Google Scholar · View at PubMed
  149. M. Lu, T. Kwan, C. Yu et al., “Peroxisome proliferator-activated receptor γ agonists promote TRAIL-induced apoptosis by reducing survivin levels via cyclin D3 repression and cell cycle arrest,” The Journal of Biological Chemistry, vol. 280, no. 8, pp. 6742–6751, 2005. View at Publisher · View at Google Scholar · View at PubMed
  150. G. He, P. Thuillier, and S. M. Fischer, “Troglitazone inhibits cyclin D1 expression and cell cycling independently of PPARγ in normal mouse skin keratinocytes,” Journal of Investigative Dermatology, vol. 123, no. 6, pp. 1110–1119, 2004. View at Publisher · View at Google Scholar · View at PubMed
  151. R. Grau, M. A. Iñiguez, and M. Fresno, “Inhibition of activator protein 1 activation, vascular endothelial growth factor, and cyclooxygenase-2 expression by 15-deoxy-Δ12,14- prostaglandin J2 in colon carcinoma cells: evidence for a redox-sensitive peroxisome proliferator-activated receptor-γ-independent mechanism,” Cancer Research, vol. 64, no. 15, pp. 5162–5171, 2004. View at Publisher · View at Google Scholar · View at PubMed
  152. D. M. Ray, F. Akbiyik, and R. P. Phipps, “The peroxisome proliferator-activated receptor γ (PPARγ) ligands 15-deoxy-Δ12,14-prostaglandin J2 and ciglitazone induce human B lymphocyte and B cell lymphoma apoptosis by PPARγ-independent mechanisms,” The Journal of Immunology, vol. 177, no. 8, pp. 5068–5076, 2006. View at Google Scholar
  153. S. Nakata, T. Yoshida, T. Shiraishi et al., “15-deoxy-Δ12,14-prostaglandin J2 induces death receptor 5 expression through mRNA stabilization independently of PPARγ and potentiates TRAIL-induced apoptosis,” Molecular Cancer Therapeutics, vol. 5, no. 7, pp. 1827–1835, 2006. View at Publisher · View at Google Scholar · View at PubMed
  154. Y. Ito, O. Yamanoshita, N. Asaeda et al., “Di(2-ethylhexyl)phthalate induces hepatic tumorigenesis through a peroxisome proliferator-activated receptor α-independent pathway,” Journal of Occupational Health, vol. 49, no. 3, pp. 172–182, 2007. View at Publisher · View at Google Scholar
  155. R. Cunard, D. DiCampli, D. C. Archer et al., “WY14,643, a PPARα ligand, has profound effects on immune responses in vivo,” The Journal of Immunology, vol. 169, no. 12, pp. 6806–6812, 2002. View at Google Scholar
  156. S. Srivastava, D. J. Conklin, S.-Q. Liu et al., “Identification of biochemical pathways for the metabolism of oxidized low-density lipoprotein derived aldehyde-4-hydroxy trans-2-nonenal in vascular smooth muscle cells,” Atherosclerosis, vol. 158, no. 2, pp. 339–350, 2001. View at Publisher · View at Google Scholar
  157. M. U. Dianzani, “4-hydroxynonenal from pathology to physiology,” Molecular Aspects of Medicine, vol. 24, no. 4-5, pp. 263–272, 2003. View at Publisher · View at Google Scholar
  158. H. Esterbauer, R. J. Schaur, and H. Zollner, “Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes,” Free Radical Biology and Medicine, vol. 11, no. 1, pp. 81–128, 1991. View at Publisher · View at Google Scholar
  159. K. Uchida, “4-hydroxy-2-nonenal: a product and mediator of oxidative stress,” Progress in Lipid Research, vol. 42, no. 4, pp. 318–343, 2003. View at Publisher · View at Google Scholar
  160. Y. C. Awasthi, G. A. S. Ansari, and S. Awasthi, “Regulation of 4-hydroxynonenal mediated signaling by glutathione S-transferases,” Methods in Enzymology, vol. 401, pp. 379–407, 2005. View at Publisher · View at Google Scholar · View at PubMed
  161. Y. Yang, S. Sharma, A. Sharma, S. Awasthi, and Y. C. Awasthi, “Lipid peroxidation and cell cycle signaling: 4-hydroxynonenal, a key molecule in stress mediated signalling,” Acta Biochimica Polonica, vol. 50, no. 2, pp. 319–336, 2003. View at Google Scholar
  162. G. Barrera, C. Di Mauro, R. Muraca et al., “Induction of differentiation in human HL-60 cells by 4-hydroxynonenal, a product of lipid peroxidation,” Experimental Cell Research, vol. 197, no. 2, pp. 148–152, 1991. View at Publisher · View at Google Scholar
  163. G. Barrera, S. Pizzimenti, R. Muraca et al., “Effect of 4-hydroxynonenal on cell cycle progression and expression of differentiation-associated antigens in HL-60 cells,” Free Radical Biology and Medicine, vol. 20, no. 3, pp. 455–462, 1996. View at Publisher · View at Google Scholar
  164. Y. C. Awasthi, R. Sharma, J. Z. Cheng et al., “Role of 4-hydroxynonenal in stress-mediated apoptosis signalling,” Molecular Aspects of Medicine, vol. 24, no. 4-5, pp. 219–230, 2003. View at Google Scholar
  165. S. Laurora, E. Tamagno, F. Briatore et al., “4-hydroxynonenal modulation of p53 family gene expression in the SK-N-BE neuroblastoma cell line,” Free Radical Biology and Medicine, vol. 38, no. 2, pp. 215–225, 2005. View at Publisher · View at Google Scholar · View at PubMed
  166. S. Pizzimenti, G. Barrera, M. U. Dianzani, and S. Brüsselbach, “Inhibition of D1, D2, and A-cyclin expression in HL-60 cells by the lipid peroxydation product 4-hydroxynonenal,” Free Radical Biology and Medicine, vol. 26, no. 11-12, pp. 1578–1586, 1999. View at Publisher · View at Google Scholar
  167. G. Barrera, S. Pizzimenti, S. Laurora, E. Moroni, B. Giglioni, and M. U. Dianzani, “4-hydroxynonenal affects pRb/E2F pathway in HL-60 human leukemic cells,” Biochemical and Biophysical Research Communications, vol. 295, no. 2, pp. 267–275, 2002. View at Publisher · View at Google Scholar
  168. S. Pizzimenti, F. Briatore, S. Laurora et al., “4-hydroxynonenal inhibits telomerase activity and hTERT expression in human leukemic cell lines,” Free Radical Biology and Medicine, vol. 40, no. 9, pp. 1578–1591, 2006. View at Publisher · View at Google Scholar · View at PubMed
  169. P. Tontonoz, L. Nagy, J. G. A. Alvarez, V. A. Thomaszy, and R. M. Evans, “PPAR-γ promotes monocyte/magrophage differentiation and uptake of oxidized LDL,” Cell, vol. 93, no. 2, pp. 241–452, 1998. View at Google Scholar
  170. S. A. Kliewer, J. M. Lenhard, T. M. Willson, I. Patel, D. C. Morris, and J. M. Lehmann, “A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation,” Cell, vol. 83, no. 5, pp. 813–819, 1995. View at Google Scholar
  171. Y. Iwashima, M. Eto, S. Horiuchi, and H. Sano, “Advanced glycation end product-induced peroxisome proliferator-activated receptor γ gene expression in the cultured mesangial cells,” Biochemical and Biophysical Research Communications, vol. 264, no. 2, pp. 441–448, 1999. View at Publisher · View at Google Scholar · View at PubMed
  172. M. Kondo, T. Oya-Ito, T. Kumagai, T. Osawa, and K. Uchida, “Cyclopentenone prostaglandins as potential inducers of intracellular oxidative stress,” The Journal of Biological Chemistry, vol. 276, no. 15, pp. 12076–12083, 2001. View at Publisher · View at Google Scholar · View at PubMed
  173. A. V. Yeldandi, M. S. Rao, and J. K. Reddy, “Hydrogen peroxide generation in peroxisome proliferator-induced oncogenesis,” Mutation Research, vol. 448, no. 2, pp. 159–177, 2000. View at Publisher · View at Google Scholar
  174. G. Muzio, A. Trombetta, M. Maggiora et al., “Arachidonic acid suppresses growth of human lung tumor A549 cells through down-regulation of ALDH3A1 expression,” Free Radical Biology and Medicine, vol. 40, no. 11, pp. 1929–1938, 2006. View at Publisher · View at Google Scholar · View at PubMed
  175. J. D. Coleman, K. S. Prabhu, J. T. Thompson et al., “The oxidative stress mediator 4-hydroxynonenal is an intracellular agonist of the nuclear receptor peroxisome proliferator-activated receptor-β/δ (PPARβ/δ),” Free Radical Biology and Medicine, vol. 42, no. 8, pp. 1155–1164, 2007. View at Publisher · View at Google Scholar · View at PubMed